

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36677

DIPLOMAT PHARMACY, INC.

(Exact name of Registrant as specified in its charter)

Michigan

(State or other jurisdiction of
incorporation or organization)

38-2063100

(IRS employer
identification number)

4100 S. Saginaw St., Flint, Michigan

(Address of principal executive offices)

48507

(Zip Code)

(888) 720-4450

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-
accelerated
filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of May 7, 2018, there were 74,132,806 outstanding shares of the registrant's no par value common stock.

DIPLOMAT PHARMACY, INC.

Form 10-Q

For the Quarter Ended March 31, 2018

INDEX

	<u>Page No.</u>
Part I — Financial Information	
Item 1 — Financial Statements	
Condensed Consolidated Balance Sheets (Unaudited)	3
Condensed Consolidated Statements of Operations (Unaudited)	4
Condensed Consolidated Statements of Cash Flows (Unaudited)	5
Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited)	6
Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2 — Management's Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3 — Qualitative and Quantitative Disclosures about Market Risk	33
Item 4 — Controls and Procedures	34
Part II — Other Information	
Item 1 — Legal Proceedings	35
Item 1A — Risk Factors	35
Item 5 — Other Information	35
Item 6 — Exhibits	36
Signatures	37

PART I
FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

DIPLOMAT PHARMACY, INC.
Condensed Consolidated Balance Sheets (Unaudited)
(Dollars in thousands)

	<u>March 31, 2018</u>	<u>December 31, 2017</u>
ASSETS		
Current assets:		
Cash and equivalents	\$ 6,040	\$ 84,251
Receivables, net	329,749	332,091
Inventories	194,755	206,603
Prepaid expenses and other current assets	13,410	11,125
Total current assets	<u>543,954</u>	<u>634,070</u>
Property and equipment, net	39,719	38,990
Capitalized software for internal use, net	31,719	36,520
Goodwill	835,633	832,624
Definite-lived intangible assets, net	375,001	392,011
Other noncurrent assets	5,883	6,208
Total assets	<u>\$ 1,831,909</u>	<u>\$ 1,940,423</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 393,185	\$ 377,489
Rebates payable	32,032	35,974
Borrowings on line of credit	140,000	188,250
Short-term debt, including current portion of long-term debt	11,500	11,500
Accrued expenses:		
Compensation and benefits	14,460	9,584
Contingent consideration	7,100	8,100
Other	16,901	20,560
Total current liabilities	<u>615,178</u>	<u>651,457</u>
Long-term debt, less current portion	444,916	521,098
Deferred income taxes	13,820	14,367
Contingent consideration	4,000	4,000
Total liabilities	<u>1,077,914</u>	<u>1,190,922</u>
Commitments and contingencies (Note 10)		
Shareholders' equity:		
Preferred stock (10,000,000 shares authorized; none issued and outstanding)	—	—
Common stock (no par value; 590,000,000 shares authorized; 74,082,806 and 73,871,424 issued and outstanding at March 31, 2018 and December 31, 2017, respectively)	621,853	619,235
Additional paid-in capital	40,902	38,450
Retained earnings	91,240	91,816
Total shareholders' equity	<u>753,995</u>	<u>749,501</u>
Total liabilities and shareholders' equity	<u>\$ 1,831,909</u>	<u>\$ 1,940,423</u>

See accompanying notes to condensed consolidated financial statements.

DIPLOMAT PHARMACY, INC.
Condensed Consolidated Statements of Operations (Unaudited)
(Dollars in thousands, except per share amounts)

	Three Months Ended	
	March 31,	
	2018	2017
Net sales	\$ 1,342,484	\$ 1,078,740
Cost of sales	(1,231,871)	(993,691)
Gross profit	110,613	85,049
Selling, general and administrative expenses	(101,922)	(76,501)
Income from operations	8,691	8,548
Other (expense) income:		
Interest expense	(10,427)	(2,049)
Other	418	33
Total other expense	(10,009)	(2,016)
(Loss) income before income taxes	(1,318)	6,532
Income tax benefit (expense)	868	(2,307)
Net (loss) income	(450)	4,225
Less net loss attributable to noncontrolling interest	—	(142)
Net (loss) income attributable to Diplomat Pharmacy, Inc.	\$ (450)	\$ 4,367
<u>Net (loss) income per common share:</u>		
Basic	\$ (0.01)	\$ 0.07
Diluted	\$ (0.01)	\$ 0.06
<u>Weighted average common shares outstanding:</u>		
Basic	73,996,313	66,886,866
Diluted	73,996,313	67,780,434

See accompanying notes to condensed consolidated financial statements.

DIPLOMAT PHARMACY, INC.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in thousands)

	Three Months Ended March 31,	
	2018	2017
Cash flows from operating activities:		
Net (loss) income	\$ (450)	\$ 4,225
Adjustments to reconcile net (loss) income to net cash provided by operating activities:		
Depreciation and amortization	23,951	15,397
Net provision for doubtful accounts	2,322	2,784
Share-based compensation expense	3,161	972
Amortization of debt issuance costs	1,132	297
Deferred income tax (benefit) expense	(547)	1,746
Contingent consideration payment	(470)	—
Other	(3)	—
Changes in operating assets and liabilities, net of business acquisitions:		
Accounts receivable	21	21,406
Inventories	11,903	14,819
Accounts payable	11,753	(20,640)
Other assets and liabilities	(4,201)	3,289
Net cash provided by operating activities	<u>48,572</u>	<u>44,295</u>
Cash flows from investing activities:		
Expenditures for property and equipment	(2,302)	(569)
Expenditures for capitalized software for internal use	(567)	(1,285)
Payments to acquire businesses, net of cash acquired	—	(26,532)
Other	3	(43)
Net cash used in investing activities	<u>(2,866)</u>	<u>(28,429)</u>
Cash flows from financing activities:		
Net payments on line of credit	(48,250)	(33,537)
Payments on long-term debt	(76,875)	(1,500)
Proceeds from long-term debt	—	25,000
Proceeds from issuance of stock upon stock option exercises	1,909	2,799
Contingent consideration payment	(530)	—
Payments of debt issuance costs	(171)	—
Net cash used in financing activities	<u>(123,917)</u>	<u>(7,238)</u>
Net (decrease) increase in cash and equivalents	(78,211)	8,628
Cash and equivalents at beginning of period	<u>84,251</u>	<u>7,953</u>
Cash and equivalents at end of period	<u>\$ 6,040</u>	<u>\$ 16,581</u>
<i>Supplemental disclosures of cash flow information:</i>		
Cash paid for interest	\$ (10,160)	\$ (1,710)
Cash refunded (paid) for income taxes	319	(117)

See accompanying notes to condensed consolidated financial statements.

DIPLOMAT PHARMACY, INC.
Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited)
(Dollars in thousands)

	Common Stock		Additional Paid-In Capital	Retained Earnings	Total Shareholders' Equity
	Shares	Amount			
Balance at January 1, 2018	73,871,424	\$ 619,235	\$ 38,450	\$ 91,816	\$ 749,501
Adoption of ASC Topic 606 (Note 3)	—	—	—	(126)	(126)
Net loss	—	—	—	(450)	(450)
Stock issued upon stock option exercises	200,677	2,461	(552)	—	1,909
Share-based compensation expense	—	—	3,161	—	3,161
Stock issued upon vesting of restricted stock units	10,705	157	(157)	—	—
Balance at March 31, 2018	74,082,806	\$ 621,853	\$ 40,902	\$ 91,240	\$ 753,995

See accompanying notes to condensed consolidated financial statements.

DIPLOMAT PHARMACY, INC.
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts)

1. DESCRIPTION OF BUSINESS

Diplomat Pharmacy, Inc. and its consolidated subsidiaries (the “Company”) is the largest independent provider of specialty pharmacy services in the United States of America (“U.S.”). The Company is focused on improving the lives of patients with complex chronic diseases while also delivering unique solutions for manufacturers, hospitals, payers and providers. The Company’s patient-centric approach positions it at the center of the healthcare continuum for treatment of complex chronic disease states, including oncology, specialty infusion therapy, immunology, hepatitis, multiple sclerosis and many other serious or long-term conditions. The Company operates as two reporting segments. The Specialty segment offers a broad range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost specialty drugs and a wide range of applications and the Pharmacy Benefit Management (“PBM”) segment provides services designed to help the Company’s customers reduce the cost and manage the complexity of their prescription drug programs. The Company dispenses to patients in all U.S. states and territories through its advanced distribution centers and manages centralized clinical call centers to deliver localized services on a national scale.

2. BASIS OF PRESENTATION

Interim Unaudited Condensed Consolidated Financial Statements

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the interim financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the financial position, results of operations, cash flows and changes in shareholders’ equity. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 1, 2018.

3. NEW ACCOUNTING STANDARDS

Adoption of New Accounting Standards

Revenue

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, *Revenue from Contracts with Customers (Topic 606)* (“Topic 606”), which supersedes the previous revenue recognition guidance under U.S. GAAP. The new standard focuses on creating a single source of revenue guidance for revenue arising from contracts with customers for all industries. The objective of the new standard is for companies to recognize revenue when it transfers the promised goods or services to its customers at an amount that represents what the company expects to be entitled to in exchange for those goods or services. In July 2015, the FASB issued ASU No. 2015-14, *Revenue from Contracts with Customers (Topic 606) Deferral of the Effective Date*, which deferred the effective date of Topic 606 by one year to annual reporting periods beginning after December 15, 2017 for public entities, though early adoption was permitted. Topic 606 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective transition method). The new standard also includes a cohesive set of disclosure requirements intended to provide users of financial

[Table of Contents](#)

statements with comprehensive information about the nature, amount, timing and uncertainty of revenue and cash flows arising from a company's contracts with customers.

On January 1, 2018, the Company adopted Topic 606 using the modified retrospective transition method. Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company recognized the cumulative effect of initially applying the new revenue recognition standard on January 1, 2018 and recorded an after-tax adjustment of \$126 to reduce beginning retained earnings. This cumulative adjustment relates to a shift in the timing of revenue recognition of dispensing prescription drugs for home delivery from the date the drugs are shipped under the Company's previous accounting policy to the date the drugs are physically delivered (which better reflects when control transfers) under the new accounting policy adopted in connection with Topic 606. The effect of this change is not significant as there is a very short timeframe from the shipment date to the physical delivery date of the prescription drugs. Additionally, in the PBM segment, prior to the adoption of Topic 606, revenue related to certain contracts was previously recognized on a net basis as the Company was considered to be acting as an agent in the transactions. The Company reassessed the principal versus agent criteria under Topic 606 and determined under the new guidance that the Company is considered to be acting as principal in these transactions and, effective January 1, 2018, began to recognize revenue on a gross basis.

As a result of applying the modified retrospective transition method, the following condensed consolidated balance sheet line items were adjusted as of January 1, 2018:

	As Reported December 31, 2017	Adjustment	As Adjusted January 1, 2018
Receivables, net	\$ 332,091	\$ (6,483)	\$ 325,608
Inventories	206,603	6,313	212,916
Total current assets	634,070	(170)	633,900
Total assets	1,940,423	(170)	1,940,253
Accrued expenses — Other	20,560	(44)	20,516
Total current liabilities	651,457	(44)	651,413
Total liabilities	1,190,922	(44)	1,190,878
Retained earnings	91,816	(126)	91,690
Total shareholders' equity	749,501	(126)	749,375
Total liabilities and shareholders' equity	1,940,423	(170)	1,940,253

[Table of Contents](#)

The following table compares the reported condensed consolidated balance sheet, statement of operations and statement of cash flows as of and for the three months ended March 31, 2018 to the as adjusted amounts had the previous revenue accounting guidance remained in effect:

	As Reported As of and For the Three Months Ended March 31, 2018	Adjustment	As Adjusted As of and for the Three Months Ended March 31, 2018
Condensed Consolidated Balance Sheet:			
Receivables, net	\$ 329,749	\$ 8,382	\$ 338,131
Inventories	194,755	(8,085)	186,670
Total current assets	543,954	297	544,251
Total assets	1,831,909	297	1,832,206
Accrued expenses — Other	16,901	78	16,979
Total current liabilities	615,178	78	615,256
Total liabilities	1,077,914	78	1,077,992
Retained earnings	91,240	219	91,459
Total shareholders' equity	753,995	219	754,214
Total liabilities and shareholders' equity	1,831,909	297	1,832,206
Condensed Consolidated Statement of Operations:			
Net sales	\$ 1,342,484	\$ (97,890)	\$ 1,244,594
Cost of sales	(1,231,871)	98,017	(1,133,854)
Gross profit	110,613	127	110,740
Income from operations	8,691	127	8,818
(Loss) income before income taxes	(1,318)	127	(1,191)
Income tax benefit (expense)	868	(34)	834
Net (loss) income	(450)	93	(357)
Net (loss) income attributable to Diplomat Pharmacy, Inc.	(450)	93	(357)
Condensed Consolidated Statement of Cash Flows:			
Net (loss) income	\$ (450)	\$ 93	\$ (357)
Accounts receivable (change)	21	(8,382)	(8,361)
Inventories (change)	11,903	8,085	19,988
Other assets and liabilities (change)	(4,201)	204	(3,997)

See the *Revenue* section in Note 4 for additional disclosures required under Topic 606.

Derivatives and Hedging

In August 2017, the FASB issued ASU No. 2017-12, *Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities* (“ASU 2017-12”). ASU 2017-12 aligns hedge accounting with risk management activities and simplifies the requirement to qualify for hedge accounting. ASU 2017-12 is effective for annual periods beginning on or after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted.

Effective January 1, 2018, the Company early adopted ASU 2017-12. There was no current impact to the Company as a result of this adoption.

Accounting Standards Issued But Not Yet Adopted*Leases*

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)* (“ASU 2016-02”), requiring lessees to recognize a right-of-use asset and a lease liability for all leases (with the exception of short-term leases) at lease commencement date. ASU 2016-02 is effective for annual periods beginning on or after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted. The Company is in the early stages of evaluating the impact that adopting ASU 2016-02 will have on its consolidated financial statements and/or notes thereto.

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES*Principles of Consolidation*

The condensed consolidated financial statements include the accounts of Diplomat Pharmacy, Inc., its wholly-owned subsidiaries, and a 51 percent owned subsidiary, formed in August 2014, which the Company controlled and which was dissolved during the fourth quarter of 2017. An investment in an entity in which the Company owns less than 20 percent and does not have the ability to exercise significant influence is accounted for under the cost method.

All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Receivables, net

Receivables, net consisted of the following:

	March 31, 2018	December 31, 2017
Trade receivables, net of allowances of \$(23,026) and \$(22,050), respectively	\$ 316,805	\$ 317,004
Rebate receivables	10,575	12,847
Other receivables	2,369	2,240
	<u>\$ 329,749</u>	<u>\$ 332,091</u>

Trade receivables are stated at the invoiced amount. Trade receivables primarily include amounts due from clients, third-party pharmacy benefit managers and insurance providers and are based on contracted prices. Trade receivables are unsecured and require no collateral. Trade receivable terms vary by payer, but generally are due within 30 days after the sale of the product or performance of the service.

Rebate receivables are amounts due from pharmaceutical manufacturers related to drug purchases by participants of the various pharmacy benefit plans that the Company manages, a portion of which, depending on contract terms, are paid back to the Company’s customers.

Inventories

Inventories consist of prescription and over-the-counter drugs and are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Prescription drugs are returnable to the Company’s vendors and fully refundable before six months of expiration, and any remaining expired drugs are relieved from inventory on a quarterly basis.

Revenue

The following table disaggregates the Company's net sales by major source:

	Three Months Ended	
	March 31,	
	2018	2017
Oncology (Specialty)	\$ 686,897	\$ 608,282
Specialty Infusion (Specialty)	165,717	131,026
Immunology (Specialty)	135,599	138,051
Other (Specialty)	164,766	201,381
PBM	191,468	—
Inter-segment eliminations	(1,963)	—
	\$ 1,342,484	\$ 1,078,740

Specialty Segment

The Company recognizes revenue from dispensing prescription drugs for home delivery at the time the drugs are physically delivered (when control transfers). Revenue from dispensing prescription drugs that are picked up by patients at an open-door or retail pharmacy location are recorded at prescription adjudication, which approximates the fill date. Each prescription claim is considered its own arrangement with the customer and is a performance obligation.

The Company accrues an estimate of fees, including direct and indirect remuneration fees ("DIR fees"), which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction at the time revenue is recognized. Changes in the Company's estimate of such fees are recorded as an adjustment to revenue when the change becomes known.

PBM Segment

The Company provides a pharmacy benefit management service, including mail order pharmacy and specialty pharmacy services, to its clients, which include Medicare Part D Plans, regional health Plans, self-insured clients and Medicaid Plans. The Company sells prescription drugs directly through its mail service dispensing pharmacy and indirectly through its contracted network of retail pharmacies. The Company recognizes revenue from the sale of prescription drugs by its mail order pharmacy service when the drugs are physically delivered (when control transfers) and by its retail pharmacy network when the claim is adjudicated. The Company's pharmacy benefit management services are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. Pharmacy benefit management services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs. The Company recognizes revenue using the gross method since the Company acts as principal in the arrangement, exercises pricing latitude and independently has a contractual obligation to pay its network pharmacy providers for benefits provided to its clients' members, and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related pharmacy benefit management services. The Company includes the total prescription price (drug ingredient cost plus dispensing fee) it has contracted with these clients as revenue, including member co-payments to pharmacies, and as cost of sales.

Net sales include (i) the portion of the price the client pays directly to the Company, net of any variable consideration including volume-related or other discounts paid back to the client, (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions and (iii) claims-based administrative fees. The Company records revenue net of manufacturer's rebates which are earned by its clients based on their plan members' utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimate claims data and its estimates of manufacturers'

rebates earned by its clients. The Company adjusts against revenues its rebates payable to clients to the actual amounts paid when such adjustments become known. The Company also adjusts revenues for refunds owed to the clients resulting from pricing and performance guarantees against defined metrics.

Sales taxes are presented on a net basis (excluded from revenue and cost) for both segments.

5. BUSINESS ACQUISITIONS

The Company accounts for its business acquisitions using the acquisition method as required by FASB Accounting Standards Codification Topic 805, *Business Combinations*. The Company ascribes significant value to the synergies and other benefits that do not meet the recognition criteria of acquired identifiable intangible assets. Accordingly, the value of these components is included within goodwill. The Company's business acquisitions described below, except a portion of LDI (defined below), were treated as asset purchases for income tax purposes and the related goodwill resulting from these business acquisitions is deductible for income tax purposes. The results of operations for acquired businesses are included in the Company's consolidated financial statements from their respective acquisition dates.

The assets acquired and liabilities assumed in the business combinations described below, including identifiable intangible assets, were based on their estimated fair values as of the acquisition date. The excess of purchase price over the estimated fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The allocation of the purchase price required management to make significant estimates in determining the fair values of assets acquired and liabilities assumed, especially with respect to identifiable intangible assets. These estimated fair values were based on information obtained from management of the acquired companies and historical experience and, with respect to the long-lived tangible and intangible assets, were made with the assistance of an independent valuation firm. These estimates included, but were not limited to, the cash flows that an asset is expected to generate in the future, and the cost savings expected to be derived from acquiring an asset, discounted at rates commensurate with the risks and uncertainties involved. For acquisitions that involved contingent consideration, the Company recognized a liability equal to the fair value of the contingent consideration obligation as of the acquisition date. The estimate of fair value of a contingent consideration obligation required subjective assumptions regarding future business results, discount rates and probabilities assigned to various potential business result scenarios. These estimates are preliminary and subject to change up to one year following each acquired entity's respective acquisition date.

LDI Holding Company LLC

On December 20, 2017, the Company acquired LDI Holding Company LLC, doing business as LDI Integrated Pharmacy Services ("LDI"). LDI is a full-service PBM based in St. Louis, Missouri. LDI's service offerings include URAC-accredited mail-order and specialty pharmacies, a national network of retail pharmacies and comprehensive clinical programs. The following table summarizes the consideration transferred to acquire LDI:

Cash	\$	521,300
4,113,188 restricted common shares		79,088
	\$	<u>600,388</u>

The above share consideration at closing is based on 4,113,188 shares, in accordance with the purchase agreement, multiplied by the per share closing market price of the Company's common stock as of December 19, 2017 (\$20.24) and multiplied by 95 percent to account for the restricted nature of the shares.

Approximately \$7,500 of the purchase consideration was deposited into an escrow account to satisfy any indemnification claims that may be made by the Company. Approximately \$5,200 was released to the sellers from escrow in March 2018.

The Company incurred acquisition-related costs of \$391 which were charged to "Selling, general and administrative expenses" during the three months ended March 31, 2018.

[Table of Contents](#)

The following table summarizes the preliminary fair values of identifiable assets acquired and liabilities assumed at the acquisition date:

Cash	\$	780
Accounts receivable		38,028
Inventories		2,857
Prepaid expenses and other current assets		750
Property and equipment		3,025
Capitalized software for internal use		425
Definite-lived intangible assets		201,523
Other noncurrent assets		148
Accounts payable		(39,530)
Accrued expenses — compensation and benefits		(2,137)
Accrued expenses — other		(1,948)
Deferred income taxes		(31,173)
Total identifiable net assets		172,748
Goodwill		427,640
	\$	<u>600,388</u>

As of March 31, 2018, the Company was still in the process of finalizing its LDI valuation and, therefore, the purchase price allocation should be considered preliminary. The preliminary purchase price allocation may be subject to further refinement upon finalization of fair valuing acquisition-date working capital, as well as completion of acquisition-related income tax assessment. The goodwill balance may be adjusted pending the completion of the valuation of the assets acquired and liabilities assumed as described above. To the extent that significant changes occur in the future, the Company will disclose such changes in the reporting period in which they occur.

Definite-lived intangible assets that were acquired and their respective useful lives are as follows:

	Useful Life	Amount
Customer relationships	10 years	\$ 184,973
Trade names and trademarks	4 years	16,550
		<u>\$ 201,523</u>

Pharmaceutical Technologies, Inc.

On November 27, 2017, the Company acquired Pharmaceuticals Technologies, Inc., doing business as National Pharmaceutical Services (“NPS”). NPS is a full-service PBM based in Omaha, Nebraska. The following table summarizes the consideration transferred to acquire NPS:

Cash	\$	34,895
835,017 restricted common shares		12,753
	\$	<u>47,648</u>

The above share consideration at closing is based on 835,017 shares, in accordance with the purchase agreement, multiplied by the per share closing market price of the Company’s common stock as of November 24, 2017 (\$16.97) and multiplied by 90 percent to account for the restricted nature of the shares.

Approximately \$9,005 of the purchase consideration was deposited into an escrow account to be held for 12 months after the closing date to satisfy any indemnification claims that may be made by the Company.

The Company incurred acquisition-related costs of \$553 which were charged to “Selling, general and administrative expenses” during the three months ended March 31, 2018.

[Table of Contents](#)

The following table summarizes the preliminary fair values of identifiable assets acquired and liabilities assumed at the acquisition date:

Cash	\$	9,851
Accounts receivable		20,622
Inventories		200
Prepaid expenses and other current assets		650
Property and equipment		13,545
Capitalized software for internal use		1,800
Definite-lived intangible assets		6,720
Accounts payable		(22,850)
Accrued expenses — compensation and benefits		(160)
Accrued expenses — other		(4,886)
Total identifiable net assets		<u>25,492</u>
Goodwill		22,156
	\$	<u>47,648</u>

As of March 31, 2018, the Company was still in the process of finalizing its NPS valuation and, therefore, the purchase price allocation should be considered preliminary. The preliminary purchase price allocation may be subject to further refinement upon finalization of fair valuing acquisition-date working capital. The goodwill balance may be adjusted pending the completion of the valuation of the assets acquired and liabilities assumed as described above. To the extent that significant changes occur in the future, the Company will disclose such changes in the reporting period in which they occur.

Definite-lived intangible assets that were acquired and their respective useful lives are as follows:

	<u>Useful Life</u>	<u>Amount</u>
Customer relationships	10 years	\$ 5,900
Trade names and trademarks	2 years	820
		<u>\$ 6,720</u>

Focus Rx Pharmacy Services Inc. and Focus Rx Inc.

On September 1, 2017, the Company acquired Focus Rx Pharmacy Services Inc. and Focus Rx Inc. (collectively, “Focus”), a specialty pharmacy focusing on infusion services located in Ronkonkoma, New York. The following table summarizes the consideration transferred to acquire Focus:

Cash	\$	17,252
374,297 restricted common shares		5,643
Contingent consideration at fair value		2,080
	\$	<u>24,975</u>

The above share consideration at closing is based on 374,297 shares, in accordance with the purchase agreement, multiplied by the per share closing market price of the Company’s common stock as of August 31, 2017 (\$16.75) and multiplied by 90 percent to account for the restricted nature of the shares.

The purchase price includes a contingent consideration arrangement that requires the Company to pay the former owners additional cash payouts of up to \$1,500 per performance period based upon the achievement of certain gross profit targets in each of the 12-month periods ending September 30, 2018 and 2019. The maximum additional cash payout is \$3,000.

Approximately \$1,200 of the purchase consideration was deposited into an escrow account to be held for 12 months after the closing date to satisfy any of the Company’s indemnification claims.

[Table of Contents](#)

The following table summarizes the preliminary fair values of identifiable assets acquired and liabilities assumed at the acquisition date:

Cash	\$	1,809
Accounts receivable		4,954
Inventories		1,178
Definite-lived intangible assets		7,100
Other noncurrent assets		22
Accounts payable		(5,122)
Accrued expenses — compensation and benefits		(156)
Total identifiable net assets		<u>9,785</u>
Goodwill		15,190
	\$	<u>24,975</u>

As of March 31, 2018, the Company was still in the process of finalizing its Focus valuation and, therefore, the purchase price allocation should be considered preliminary. The preliminary purchase price allocation may be subject to further refinement upon finalization of fair valuing acquisition-date working capital. The goodwill balance may be adjusted pending the completion of the valuation of the assets acquired and liabilities assumed as described above. To the extent that significant changes occur in the future, the Company will disclose such changes in the reporting period in which they occur.

Definite-lived intangible assets that were acquired and their respective useful lives are as follows:

	Useful Life	Amount
Patient relationships	7 years	\$ 3,700
Non-compete employment agreements	3 years	2,200
Trade names and trademarks	3 years	1,200
		<u>\$ 7,100</u>

Accurate Rx Pharmacy Consulting, LLC

On July 5, 2017, the Company acquired Accurate Rx Pharmacy Consulting, LLC (“Accurate”), a specialty pharmacy focusing on infusion services located in Columbia, Missouri. The following table summarizes the consideration transferred to acquire Accurate:

Cash	\$	9,408
131,108 restricted common shares		1,776
Contingent consideration at fair value		1,980
	\$	<u>13,164</u>

The above share consideration at closing is based on 131,108 shares, in accordance with the purchase agreement, multiplied by the per share closing market price of the Company’s common stock as of July 3, 2017 (\$15.05) and multiplied by 90 percent to account for the restricted nature of the shares.

The purchase price includes a contingent consideration arrangement that requires the Company to pay the former owners additional cash payouts of up to \$3,600 per performance period based upon the achievement of certain gross profit targets in each of the 12-month periods ending July 31, 2018 and 2019. The maximum additional cash payout is \$7,200.

Approximately \$1,000 of the purchase consideration was deposited into an escrow account to be held for 15 months after the closing date to satisfy any of the Company’s indemnification claims.

[Table of Contents](#)

The following table summarizes the fair values of identifiable assets acquired and liabilities assumed at the acquisition date:

Cash	\$	1,295
Accounts receivable		2,196
Inventory		936
Prepaid expenses and other current assets		34
Definite-lived intangible assets		3,420
Other noncurrent assets		3
Accounts payable		(3,303)
Accrued expenses — compensation and benefits		(152)
Accrued expenses — other		(6)
Total identifiable net assets		4,423
Goodwill		8,741
	\$	<u>13,164</u>

Definite-lived intangible assets that were acquired and their respective useful lives are as follows:

	Useful Life	Amount
Patient relationships	7 years	\$ 2,100
Non-compete employment agreements	5 years	670
Trade names and trademarks	3 years	650
		<u>\$ 3,420</u>

WRB Communications, LLC

On May 8, 2017, the Company acquired WRB Communications, LLC (“WRB”), a communications and contact center company based in Chantilly, Virginia that specializes in relationship management programs for leading pharmaceutical manufacturers and service organizations. The following table summarizes the consideration transferred to acquire WRB:

Cash	\$	26,804
299,325 restricted common shares		4,291
Contingent consideration at fair value		530
	\$	<u>31,625</u>

The above share consideration at closing is based on 299,325 shares, in accordance with the purchase agreement, multiplied by the per share closing market price of the Company’s common stock as of May 5, 2017 (\$15.93) and multiplied by 90 percent to account for the restricted nature of the shares.

The purchase price includes a contingent consideration arrangement that requires the Company to pay the former owners additional cash payouts of up to \$500 per performance period based upon the achievement of certain earnings before interest, taxes, depreciation and amortization targets in each of the 12-month periods ending May 31, 2018 and 2019. During the fourth quarter of 2017, the Company guaranteed a full payout to allow for the acceleration of certain integration activities. The former owners received \$1,000 in cash in January 2018.

Approximately \$1,950 of the purchase consideration was deposited into an escrow account to be held for 18 months after the closing date to satisfy any of the Company’s indemnification claims.

[Table of Contents](#)

The following table summarizes the fair values of identifiable assets acquired and liabilities assumed at the acquisition date:

Cash	\$	1,018
Accounts receivable		2,593
Prepaid expenses and other current assets		179
Property and equipment		498
Definite-lived intangible assets		7,730
Other noncurrent assets		24
Accounts payable		(100)
Accrued expenses — other		(498)
Total identifiable net assets		11,444
Goodwill		20,181
	\$	<u>31,625</u>

Definite-lived intangible assets that were acquired and their respective useful lives are as follows:

	Useful Life	Amount
Customer relationships	7 years	\$ 5,200
Non-compete employment agreements	4 years	1,530
Trade names and trademarks	2 years	1,000
		<u>\$ 7,730</u>

Comfort Infusion, Inc.

On March 22, 2017, the Company acquired Comfort Infusion, Inc. (“Comfort”), a specialty pharmacy and infusion services company based in Birmingham, Alabama that specializes in intravenous immune globulin therapy to support patients’ immune systems. The following table summarizes the consideration transferred to acquire Comfort:

Cash	\$	10,613
Contingent consideration at fair value		3,800
	\$	<u>14,413</u>

The purchase price includes a contingent consideration arrangement that requires the Company to pay the former owners additional cash payouts of up to \$2,000 per performance period based upon the achievement of certain gross profit targets in each of the 12-month periods ending March 31, 2018, 2019 and 2020. The maximum payout of contingent consideration is \$6,000.

Approximately \$1,050 of the purchase consideration was deposited into an escrow account to be held for 18 months after the closing date to satisfy any of the Company’s indemnification claims.

The Company incurred acquisition-related costs of \$140 which were charged to “Selling, general and administrative expenses” during the three months ended March 31, 2017.

[Table of Contents](#)

The following table summarizes the fair values of identifiable assets acquired and liabilities assumed at the acquisition date:

Cash	\$	104
Accounts receivable		575
Inventories		118
Prepaid expenses and other current assets		15
Definite-lived intangible assets		2,400
Other noncurrent assets		5
Accounts payable		(372)
Accrued expenses — other		(101)
Total identifiable net assets		<u>2,744</u>
Goodwill		11,669
	\$	<u><u>14,413</u></u>

Definite-lived intangible assets that were acquired and their respective useful lives are as follows:

	Useful Life	Amount
Physician relationships	7 years	\$ 1,200
Non-compete employment agreements	5 years	1,200
		<u>\$ 2,400</u>

Affinity Biotech, Inc.

On February 1, 2017, the Company acquired Affinity Biotech, Inc. (“Affinity”), a specialty pharmacy and infusion services company based in Houston, Texas that provides treatments and nursing services for patients with hemophilia. The following table summarizes the consideration transferred to acquire Affinity:

Cash	\$	17,377
Contingent consideration at fair value		35
	\$	<u><u>17,412</u></u>

The purchase price includes a contingent consideration arrangement that requires the Company to pay the former owners an additional cash payout based upon the achievement of a certain earnings before interest, taxes, depreciation and amortization target in the 12-month period ending February 28, 2018. The maximum payout of contingent consideration is \$4,000.

Approximately \$2,000 of the purchase consideration was deposited into an escrow account to be held for 18 months after the closing date to satisfy any of the Company’s indemnification claims.

The Company incurred acquisition-related costs of \$224 which were charged to “Selling, general and administrative expenses” during the three months ended March 31, 2017.

[Table of Contents](#)

The following table summarizes the fair values of identifiable assets acquired and liabilities assumed at the acquisition date:

Cash	\$	1,043
Accounts receivable		3,433
Inventories		79
Prepaid expenses and other current assets		74
Definite-lived intangible assets		5,100
Other noncurrent assets		5
Accounts payable		(1,075)
Accrued expenses — compensation and benefits		(144)
Accrued expenses — other		(25)
Total identifiable net assets		8,490
Goodwill		8,922
	\$	<u>17,412</u>

Definite-lived intangible assets that were acquired and their respective useful lives are as follows:

	Useful Life	Amount
Patient relationships	7 years	\$ 4,000
Non-compete employment agreements	5 years	1,100
		<u>\$ 5,100</u>

Pro Forma Operating Results

The following unaudited pro forma summary presents consolidated financial information as if the Accurate, Affinity, Comfort, Focus, LDI, NPS and WRB acquisitions had occurred on January 1, 2016. The unaudited pro forma results reflect certain adjustments related to the acquisitions, such as amortization expense resulting from intangible assets acquired and adjustments to reflect the Company's borrowings and tax rates. Accordingly, such pro forma operating results were prepared for comparative purposes only and do not purport to be indicative of what would have occurred had the acquisitions been made as of the as if date or of results that may occur in the future .

	Three Months Ended March 31, 2017
Net sales	\$ 1,197,903
Net loss attributable to Diplomat Pharmacy, Inc.	\$ (1,537)
Net loss per common share — basic & diluted	\$ (0.02)

6. FAIR VALUE MEASUREMENTS

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy was established, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets;

[Table of Contents](#)

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

An asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:

- A. *Market approach*: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
- B. *Cost approach*: Amount that would be required to replace the service capacity of an asset (replacement cost).
- C. *Income approach*: Techniques to convert future amounts to a single present amount based upon market expectations (including present value techniques, option-pricing and excess earnings models).

The following table presents the placement in the fair value hierarchy of assets and liabilities that are measured and disclosed at fair value on a recurring basis:

	<u>Asset / (Liability)</u>	<u>Valuation Level 3</u>	<u>Technique</u>
March 31, 2018:			
Contingent consideration	\$ (11,100)	\$ (11,100)	C
December 31, 2017:			
Contingent consideration	\$ (12,100)	\$ (12,100)	C

The following table sets forth a roll forward of the Level 3 measurements for the three months ended March 31, 2018:

	<u>Contingent Consideration</u>
Balance at January 1, 2018	\$ (12,100)
Payments	1,000
Balance at March 31, 2018	<u>\$ (11,100)</u>

The carrying amounts of the Company's financial instruments — consisting primarily of cash and cash equivalents, accounts receivable, accounts payable, and other liabilities — approximate their estimated fair values due to the relative short-term nature of the amounts. The carrying amount of debt approximates fair value due to variable interest rates at customary terms and rates the Company could obtain in current financing.

7. GOODWILL AND DEFINITE-LIVED INTANGIBLE ASSETS

The following table sets forth a roll forward of goodwill for the three months ended March 31, 2018:

Balance at January 1, 2018	\$ 832,624
Miscellaneous	3,009
Balance at March 31, 2018	<u>\$ 835,633</u>

[Table of Contents](#)

Goodwill by reporting segment is as follows:

	March 31, 2018	December 31, 2017
PBM	\$ 449,796	\$ 446,740
Specialty	385,837	385,884
	<u>\$ 835,633</u>	<u>\$ 832,624</u>

Definite-lived intangible assets consisted of the following:

	March 31, 2018			December 31, 2017		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Customer relationships	\$ 196,073	\$ (6,628)	\$ 189,445	\$ 196,073	\$ (1,141)	\$ 194,932
Patient relationships	170,100	(54,304)	115,796	170,100	(49,643)	120,457
Non-compete employment agreements	61,389	(33,722)	27,667	61,389	(30,560)	30,829
Trade names and trademarks	44,020	(16,465)	27,555	44,020	(13,624)	30,396
Physician relationships	21,700	(7,162)	14,538	21,700	(6,303)	15,397
	<u>\$ 493,282</u>	<u>\$ (118,281)</u>	<u>\$ 375,001</u>	<u>\$ 493,282</u>	<u>\$ (101,271)</u>	<u>\$ 392,011</u>

Amortization expense for the three months ended March 31, 2018 and 2017 was \$17,010 and \$9,685, respectively.

8. DEBT

The Company had \$473,125 and \$550,000 in outstanding term loans as of March 31, 2018 and December 31, 2017, respectively. Unamortized debt issuance costs of \$16,709 and \$17,402 as of March 31, 2018 and December 31, 2017, respectively, are presented in the condensed consolidated balance sheets as direct deductions from the outstanding debt balances. The Company also had \$140,000 and \$188,250 outstanding on its line of credit as of March 31, 2018 and December 31, 2017, respectively. The Company had \$110,000 and \$61,750 available to borrow on its line of credit at March 31, 2018 and December 31, 2017, respectively.

The interest rates the Company pays under its credit facility are a function of a defined margin above LIBOR. The Company's Term Loan A and Term Loan B interest rates were 4.38 percent and 6.10 percent, respectively, at March 31, 2018 and 4.04 percent and 6.04 percent, respectively, at December 31, 2017. The Company's line of credit interest rate was 4.38 percent and 4.04 percent at March 31, 2018 and December 31, 2017, respectively. The Company is charged a monthly unused commitment fee ranging from 0.3 percent to 0.4 percent on the average unused daily balance on its \$250,000 line of credit.

The Company's credit facility contains certain financial and non-financial covenants. The Company was in compliance with all such covenants as of March 31, 2018 and December 31, 2017.

9. SHARE-BASED COMPENSATION

A summary of the Company's stock option activity as of and for the three months ended March 31, 2018 is as follows:

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding at January 1, 2018	6,108,292	\$ 18.62	8.5	\$ 25,777
Granted	330,135	20.68		
Exercised	(200,677)	9.51		
Expired/cancelled	(443,167)	21.91		
Outstanding at March 31, 2018	<u>5,794,583</u>	<u>\$ 18.82</u>	<u>8.5</u>	<u>\$ 22,229</u>
Exercisable at March 31, 2018	<u>1,503,271</u>	<u>\$ 18.68</u>	<u>7.2</u>	<u>\$ 9,632</u>

The Company recorded share-based compensation expense associated with stock options of \$2,155 and \$896 for the three months ended March 31, 2018 and 2017, respectively.

The Company granted service-based awards of 330,135 options to purchase common stock to key employees under its 2014 Omnibus Incentive Plan (the "2014 Plan") during the first quarter of 2018, of which 225,135 and 105,000 options become exercisable in installments of 33.3 percent and 25 percent, respectively, per year, beginning on the first anniversary of the grant date. These options have a maximum term of ten years.

The 330,135 options to purchase common stock that were granted during the three months ended March 31, 2018 have a weighted average grant date fair value of \$8.42 per option. The grant date fair values of these stock option awards were estimated using the Black-Scholes-Merton option pricing model using the assumptions set forth in the following table :

Exercise price	\$20.52 - \$21.01
Expected volatility	36.06% - 38.15%
Expected dividend yield	0%
Risk-free rate for expected term	2.33% - 2.71%
Expected life (in years)	6.00 - 6.25

Estimating grant date fair values for employee stock options requires management to make assumptions regarding expected volatility of value of those underlying shares, the risk-free rate over the expected life of the stock options and the date on which share-based payments will be settled. Expected volatility is based on a weighted average of the Company's historic volatility and an implied volatility for a group of industry-relevant healthcare companies as of the measurement date. Risk-free rate is determined based upon U.S. Treasury rates over the estimated expected option lives. Expected dividend yield is zero as the Company does not anticipate that any dividends will be declared during the expected term of the options. The expected term of options granted is calculated using the simplified method (the midpoint between the end of the vesting period and the end of the maximum term). Forfeitures are accounted for when they occur.

Restricted Stock Units (“RSU” or “RSUs”)

A summary of the Company’s RSU activity as of and for the three months ended March 31, 2018 is as follows:

	Number of RSUs	Weighted Average Grant Date Fair Value
Outstanding at January 1, 2018	66,639	\$ 14.65
Granted	855,728	20.74
Vested and issued	(10,705)	14.65
Expired/cancelled	(3,095)	14.65
Outstanding at March 31, 2018	<u>908,567</u>	<u>\$ 20.39</u>
Vested and unissued at March 31, 2018	<u>21,203</u>	<u>\$ 23.27</u>

The Company granted 716,216 service-based RSUs to key employees under its 2014 Plan during the first quarter of 2018. The value of an RSU is determined by the market value of the Company’s common stock at the date of grant. This value is recorded as compensation expense on a straight-line basis over the vesting period, which is three years for 646,867 of the granted RSUs and six months for the remaining 69,349 RSUs.

The Company also granted 139,512 performance-based RSUs to key employees under its 2014 Plan during the first quarter of 2018, which will be earned or forfeited based upon the Company’s performance relative to specified adjusted earnings before interest, taxes, depreciation and amortization goals for the year ending December 31, 2018. The earned RSUs, if any, will vest in three equal installments, with the first installment vesting upon the earlier of the date that the Company files its Annual Report on Form 10-K or Audit Committee confirmation of the satisfaction of the applicable performance goals, with the remaining installments vesting annually thereafter. The Company is accounting for these performance-based RSUs under the current presumption of 50 percent earned and 50 percent forfeited.

The Company recorded share-based compensation expense associated with RSUs of \$868 and \$0 for the three months ended March 31, 2018 and 2017, respectively.

Restricted Stock Awards (“RSA” or RSAs”)

A summary of the Company’s RSA activity as of and for the three months ended March 31, 2018 is as follows:

	Number of Shares Subject to Restriction	Weighted Average Grant Date Fair Value
Nonvested at January 1, 2018	34,291	\$ 17.45
Vested	(2,560)	14.65
Nonvested at March 31, 2018	<u>31,731</u>	<u>\$ 17.68</u>

Under the 2014 Plan, the Company issued RSAs to non-employee directors. The value of a RSA is determined by the market value of the Company’s common stock at the date of grant. The value of a RSA is recorded as share-based compensation expense on a straight-line basis over the vesting period, which is typically one year.

The Company recorded share-based compensation expense associated with RSAs of \$138 and \$76 for the three months ended March 31, 2018 and 2017, respectively.

10. CONTINGENCIES

On November 10, 2016, a putative class action complaint was filed in the U.S. District Court for the Eastern District of Michigan against Diplomat Pharmacy, Inc. and certain officers of the Company. Following appointment of lead plaintiffs and lead counsel, an amended complaint was filed on April 11, 2017. The amended complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in connection with public filings made between February 29, 2016 and November 2, 2016 (the “potential class period”). The plaintiff seeks to represent a class of shareholders who purchased stock in the potential class period. The complaint seeks unspecified monetary damages and other relief. The Company filed a motion to dismiss the amended complaint on May 24, 2017. The court issued an order denying the Company’s motion to dismiss on January 19, 2018. The Company filed a motion for reconsideration of its motion to dismiss on February 2, 2018. The Company believes the complaint and allegations to be without merit and intends to vigorously defend itself against the action. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on its results of operations, financial condition or cash flows.

On February 10, 2017, the Company’s Board of Directors (the “Board”) received a demand letter from a purported shareholder containing allegations similar to those contained in the putative class action complaint described above. The letter demanded that the Board take action to remedy the alleged violations. In response, the Board established a Special Independent Committee of its disinterested and independent members to investigate the claims. Subsequently, on June 2, 2017, the shareholder filed a putative shareholder’s derivative lawsuit in the Michigan Circuit Court for the County of Genesee regarding the same matters alleged in the demand letter. The complaint names the Company as a nominal defendant and names a number of the Company’s current and former officers and directors as defendants. The complaint seeks unspecified monetary damages and other relief. In connection with the ongoing Special Independent Committee investigation, on July 20, 2017, by agreement between the Company and the shareholder, the court ordered a stay of legal proceedings for 90 days, after which time by further agreement of the Company and the shareholder, the court has extended the stay until July 2, 2018. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on its results of operations, financial condition or cash flows.

The results of legal proceedings are often uncertain and difficult to predict, and the Company could from time to time incur judgments, enter into settlements, materially change its business practices or technologies or revise its expectations regarding the outcome of certain matters. In addition, the costs incurred in litigation can be substantial, regardless of the outcome.

The Company’s business of providing specialized pharmacy services and other related services may subject it to litigation and liability for damages in the ordinary course of business. Nevertheless, the Company believes there are no other legal proceedings, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business, financial position, cash flows or results of operations.

11. (LOSS) INCOME PER COMMON SHARE

The following table sets forth the computation of basic and diluted (loss) income per common share:

	Three Months Ended March 31,	
	2018	2017
Numerator:		
Net (loss) income attributable to Diplomat Pharmacy, Inc.	\$ (450)	\$ 4,367
Denominator:		
Weighted average common shares outstanding, basic	73,996,313	66,886,866
Weighted average dilutive effect of stock options, RSAs and RSUs	—	893,568
Weighted average common shares outstanding, diluted	73,996,313	67,780,434
Net (loss) income per common share:		
Basic	\$ (0.01)	\$ 0.07
Diluted	\$ (0.01)	\$ 0.06

The Company recognized a net loss for the three months ended March 31, 2018. As a result, the diluted loss per share is the same as the basic loss per share as any potentially dilutive securities would reduce the loss per share. In the absence of a net loss, service-based and earned performance-based stock options to purchase a weighted average of 4,011,211 common shares would have been excluded from the computation of diluted weighted average common shares outstanding for the three months ended March 31, 2018 as inclusion of such options would be anti-dilutive. Performance-based stock options to purchase up to a weighted average of 574,138 common shares would have been excluded from the computation of diluted weighted average common shares outstanding for the three months ended March 31, 2018 as all performance conditions were not satisfied as of March 31, 2018. Weighted average service-based RSUs of 51,553 common shares would have been excluded from the computation of diluted weighted average common shares outstanding for the three months ended March 31, 2018 as inclusion of such RSUs would be anti-dilutive. Weighted average performance-based RSUs of 7,751 common shares would have been excluded from the computation of diluted weighted average common shares outstanding for the three months ended March 31, 2018 as all performance conditions were not satisfied as of March 31, 2018.

Service-based and earned performance-based stock options to purchase a weighted average of 2,433,510 common shares were excluded from the computation of diluted weighted average common shares outstanding for the three months ended March 31, 2017 as inclusion of such options would be anti-dilutive. Weighted average RSAs of 2,560 common shares were excluded from the computation of diluted weighted average common shares outstanding for the three months ended March 31, 2017 as inclusion of such shares would be anti-dilutive.

12. OPERATIONS BY REPORTING SEGMENT

Effective January 1, 2018, the Company reports in two operating segments: Specialty and PBM. The Specialty segment offers a broad range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost specialty drugs and a wide range of applications and the PBM segment provides services designed to help the Company's customers reduce the cost and manage the complexity of their prescription

[Table of Contents](#)

drug programs. The Company evaluates segment performance principally upon net sales and gross profit. Net sales, cost of sales and gross profit information by segment are as follows:

	Three Months Ended March 31,					
	Net Sales		Cost of Sales		Gross Profit	
	2018	2017	2018	2017	2018	2017
Specialty	\$ 1,152,979	\$ 1,078,740	\$ (1,059,924)	\$ (993,691)	\$ 93,055	\$ 85,049
PBM	191,468	—	(173,910)	—	17,558	—
Inter-segment eliminations	(1,963)	—	1,963	—	—	—
	<u>\$ 1,342,484</u>	<u>\$ 1,078,740</u>	<u>\$ (1,231,871)</u>	<u>\$ (993,691)</u>	<u>\$ 110,613</u>	<u>\$ 85,049</u>

Total assets by segment are as follows:

	March 31, 2018	December 31, 2017
Specialty	\$ 1,109,656	\$ 1,190,188
PBM	722,253	750,235
	<u>\$ 1,831,909</u>	<u>\$ 1,940,423</u>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share, per patient, and per prescription data)

The following Management's Discussion and Analysis of financial condition and results of operations ("MD&A") should be read in conjunction with the condensed consolidated financial statements (unaudited), related notes, and other financial information appearing elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017, which was filed on March 1, 2018 with the Securities and Exchange Commission ("SEC").

Forward-Looking Statements

Certain statements contained or incorporated in this Quarterly Report on Form 10-Q which are not statements of historical fact constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. Words such as "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "future," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "will," and similar terms and phrases, or the negative thereof, utilized in discussions of future operating or financial performance signify forward-looking statements.

The forward-looking statements contained in this report are based on management's good-faith belief and reasonable judgment based on current information. The forward-looking statements are qualified by important factors, risks, and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those in the forward-looking statements, including those described elsewhere in this report, as well as in our Annual Report on Form 10-K for the year ended December 31, 2017 and subsequent reports filed with or furnished to the SEC. Any forward-looking statement made by us in this report speaks only as of the date hereof or as of the date specified herein. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable laws or regulations.

Overview

Diplomat Pharmacy, Inc. (the "Company," "Diplomat," "our," "us," or "we") is the largest independent provider of specialty pharmacy services in the United States of America ("U.S."). We are focused on improving the lives of patients with complex chronic diseases while also delivering unique solutions for manufacturers, hospitals, payers and providers. Our patient-centric approach positions us at the center of the healthcare continuum for treatment of complex chronic diseases. We offer a broad range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost specialty drugs (many of which can cost more than \$100,000 per patient, per year) and a wide range of applications and pharmacy benefit management ("PBM") services designed to help our customers reduce the cost and manage the complexity of their prescription drug programs. We have expertise across a broad range of high-growth specialty therapeutic categories, including oncology, immunology, specialty infusion therapy, hepatitis, multiple sclerosis and many other serious or long-term conditions. We dispense to patients in all U.S. states and territories through our advanced distribution centers and manage centralized clinical call centers to deliver localized services on a national scale. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence.

[Table of Contents](#)

Our revenue is derived from: (i) customized care management programs we deliver to our patients, including the dispensing of their specialty medications and (ii) PBM services that we provide to our customers. Because the therapeutic disease states primarily addressed by our specialty pharmacy services generally require multiyear or lifelong therapy, our focus on complex chronic diseases helps drive recurring revenue and sustainable growth. Our specialty pharmacy services revenue growth is primarily driven by manufacturer price inflation, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and the addition of new clients. Going forward, we expect an aging population and attendant increase in prescription spending to drive demand for our PBM services.

Our recent and historical revenue growth has largely been driven by our position as a leader in the oncology, specialty infusion and immunology therapeutic categories. For the three months ended March 31, 2018 and 2017, we generated approximately 86 percent and 81 percent, respectively, of our Specialty segment revenue in these categories.

We expect our revenue growth to continue to be driven by a highly visible and recurring base of prescription volume and revenues, favorable demographic trends, advanced clinical developments, expanding drug pipelines, earlier detection of chronic diseases, improved access to medical care, mix shift toward higher-cost specialty drugs and manufacturer price increases. In addition, we believe our expanding breadth of services, our growing penetration with new customers and our access to limited-distribution drugs will help us achieve sustainable revenue growth in the future. Further, we believe that limited distribution is becoming the delivery system of choice for many specialty drug manufacturers because it is conducive to smaller patient populations, facilitates high patient engagement, clinical expertise and elevated focus on service, and because it allows for real-time patient-specific (albeit de-identified) data. Accordingly, we believe our current portfolio of more than 100 limited-distribution drugs, all of which are commercially available, is important to our revenue growth. For our PBM services, we expect our revenue to be propelled by rising drug prices and a growth in specialty drug spend, as well as a shift in the marketplace of drug coverage from a medical benefit to a pharmacy benefit, and the increasing complexity and required support for Medicare Part D programs.

We also provide specialty pharmacy support services to hospitals and health systems. Through many of these partners, we earn revenue by providing clinical and administrative support services on a fee-for-service basis to help them dispense specialty medications.

Key Performance Metrics

We regularly review a number of metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions :

	Three Months Ended	
	March 31,	
	2018	2017
Specialty		
Prescriptions dispensed	223,000	220,000
Net sales per prescription dispensed	\$ 5,142	\$ 4,909
Gross profit per prescription dispensed	\$ 396	\$ 383
PBM		
Prescriptions filled (adjusted to 30-day equivalent)(1)	2,181,000	—
Gross profit per prescription filled	\$ 8	\$ —

(1) A 90-day prescription is counted as three 30-day prescriptions filled

Prescription Data (rounded to the nearest thousand)

Specialty prescriptions dispensed represent prescriptions filled and dispensed by Diplomat to patients, or in rare cases, to physicians. Our volume for the three months ended March 31, 2018 was approximately 223,000 prescriptions dispensed, a 1.4 percent increase compared to approximately 220,000 prescriptions dispensed for the three months

ended March 31, 2017. The volume increase was due to access to drugs that were new in the past year and growth through payor relationships. Prescriptions dispensed adjusted to a 30-day equivalent by our recently acquired PBM was approximately 2,181,000 for the three months ended March 31, 2018.

Other Metrics

Other key metrics used in analyzing our business are net sales per prescription dispensed and gross profit per prescription dispensed. Net sales per prescription dispensed represent total prescription revenue from prescriptions dispensed by Diplomat divided by the number of prescriptions dispensed by Diplomat. Gross profit per prescription dispensed represents gross profit from prescriptions dispensed by Diplomat divided by the number of prescriptions dispensed by Diplomat. Total prescription revenue from prescriptions dispensed includes all revenue collected from patients, third-party payers and various patient assistance programs, as well as revenue collected from pharmaceutical manufacturers for data and other services directly tied to the actual dispensing of their drug(s). Gross profit represents total prescription revenue from prescriptions dispensed less the cost of the drugs purchased, including performance-related rebates paid by manufacturers to us, which are recorded as a reduction to cost of sales.

Components of Results of Operations

Net Sales

Our Specialty segment recognizes revenue for a dispensed prescription drug at time of delivery (when control transfers) and at prescription adjudication (which approximates the fill date) for patient pick up at open door or retail pharmacy locations. We can earn revenue from multiple sources for any one claim, including the primary insurance plan, the secondary insurance plan, the tertiary insurance plan, the patient co-pay and patient assistance programs. Specialty's net sales also include revenue from pharmaceutical manufacturers and other outside companies for data reporting or additional services rendered for dispensed prescriptions. Service revenue is primarily derived from fees earned by us from hospital pharmacies for patient support that is provided by us to those non-Diplomat pharmacies to dispense specialty drugs to patients. The hospital pharmacies dispense the drug and pay us a service fee for clinically and administratively servicing their patients.

Our PBM segment recognizes revenue from the sale of prescription drugs by its mail order pharmacy service when the drugs are physically delivered (when control transfers) and by its retail pharmacy network when the claim is adjudicated. Our PBM segment recognizes revenue using the gross method since they act as principal in the arrangement, exercise pricing latitude and independently have a contractual obligation to pay their network pharmacy providers for benefits provided to their clients' members, and assume primary responsibility for fulfilling the promise to provide prescription drugs to their client plan members while also performing the related pharmacy benefit management services. Our PBM segment includes the total prescription price (drug ingredient cost plus dispensing fee) they have contracted with their clients as revenue, including member co-payments to pharmacies, and as cost of sales.

Cost of Sales

Cost of sales primarily represents the purchase price of the drugs that we ultimately dispense. These drugs are purchased directly from the manufacturer or from an authorized wholesaler and the purchase price is negotiated with the selling entity. In general, period-over-period percentage changes in cost of sales will move directionally with period-over-period percentage changes in net sales for prescription dispensing transactions. This is due to the mathematical relationship between average wholesale price ("AWP") and wholesale acquisition cost ("WAC"), where most commonly AWP equals WAC multiplied by 1.20, and our contractual relationships to purchase at a discount off WAC and receive reimbursement at a discount off AWP. The discounts off AWP and WAC that we receive vary significantly by drug and by contract. Rebates we receive from manufacturers are reflected as reductions to cost of sales when they are earned.

Selling, General and Administrative Expenses ("SG&A")

Our operating expenses primarily consist of employee and employee-related costs, outbound prescription drug

[Table of Contents](#)

transportation and logistics costs, and amortization expense from definite-lived intangible assets associated with our acquired entities. Our employee and employee-related costs relate to both our patient-facing personnel and our non-patient-facing support and administrative personnel. Other operating expenses consist of occupancy and other indirect costs, insurance costs, professional fees and other general overhead expenses. We expect that general and administrative expenses will continue to increase as we incur additional expenses related to our growth.

Other Expense

Other expense primarily consists of interest expense associated with our debt.

Results of Operations

The following table provides statements of operations data for each of the periods presented:

	Three Months Ended March 31,	
	2018	2017
Net sales	\$ 1,342,484	\$ 1,078,740
Cost of sales	(1,231,871)	(993,691)
Gross profit	110,613	85,049
SG&A	(101,922)	(76,501)
Income from operations	8,691	8,548
Other (expense) income:		
Interest expense	(10,427)	(2,049)
Other	418	33
Total other expense	(10,009)	(2,016)
(Loss) income before income taxes	(1,318)	6,532
Income tax benefit (expense)	868	(2,307)
Net (loss) income	(450)	4,225
Less net loss attributable to noncontrolling interest	—	(142)
Net (loss) income attributable to Diplomat Pharmacy, Inc.	\$ (450)	\$ 4,367

Net Sales

Net sales for the three months ended March 31, 2018 were \$1,342,484, a \$263,744 or 24 percent increase, compared to \$1,078,740 for the three months ended March 31, 2017. This increase was primarily the result of approximately \$223,000 from our recent acquisitions, approximately \$85,000 from the impact of manufacturer price increases and approximately \$54,000 from drugs that were new in the past twelve months. These increases were partially offset by a decrease in hepatitis C business versus the prior year period, reimbursement compression and drug mix.

Cost of Sales

Cost of sales for the three months ended March 31, 2018 was \$1,231,871, a \$238,180 or 24 percent increase, compared to \$993,691 for the three months ended March 31, 2017. This increase was primarily the result of the same factors that drove the increase in our net sales over the same time period. Cost of sales was 91.8 percent and 92.1 percent of net sales for the three months ended March 31, 2018 and 2017, respectively. The increase in gross margin from 7.9 percent to 8.2 percent for the three months ended March 31, 2017 and 2018, respectively, was primarily due to the impact of our acquisitions and the impact of manufacturer price increases.

SG&A

SG&A for the three months ended March 31, 2018 were \$101,922, a \$25,421 increase, compared to \$76,501 for the three months ended March 31, 2017. Total employee cost increased by \$12,167, inclusive of a \$2,189 increase in share-based compensation expense and a \$677 increase in severance expense. The increased employee expense was primarily attributable to the increased clinical and administrative complexity associated with our mix of business. Amortization expense from definite-lived intangible assets associated with our acquired entities increased \$7,520. The remaining increase was in all other SG&A to support our business including consulting, freight and other miscellaneous expenses. As a percent of net sales, SG&A accounted for 7.6 percent for the three months ended March 31, 2018 compared to 7.1 percent for the three months ended March 31, 2017.

Other Expense

Our other expense was \$10,009 and \$2,016 for the three months ended March 31, 2018 and 2017, respectively, and is primarily comprised of interest expense. The \$8,378 increase in interest expense was due to significantly higher average borrowings in the first quarter of 2018 resulting from recent acquisitions.

Income Tax Benefit (Expense)

Our income tax benefit (expense) for the three months ended March 31, 2018 and 2017 was \$868 and \$(2,307), respectively, resulting in effective tax rates of 66 percent and 35 percent, respectively. Income tax for the first quarter of 2018 included the recognition of net tax benefits related to share-based awards, which favorably impacted the effective tax rate by 20 percent.

Net sales, cost of sales and gross profit information by segment are as follows:

	Three Months Ended March 31,					
	Net Sales		Cost of Sales		Gross Profit	
	2018	2017	2018	2017	2018	2017
Specialty	\$ 1,152,979	\$ 1,078,740	\$ (1,059,924)	\$ (993,691)	\$ 93,055	\$ 85,049
PBM	191,468	—	(173,910)	—	17,558	—
Inter-segment eliminations	(1,963)	—	1,963	—	—	—
	<u>\$ 1,342,484</u>	<u>\$ 1,078,740</u>	<u>\$ (1,231,871)</u>	<u>\$ (993,691)</u>	<u>\$ 110,613</u>	<u>\$ 85,049</u>

Net Sales — Specialty

Net sales for the three months ended March 31, 2018 were \$1,152,979, a \$74,239 or 7 percent increase, compared to \$1,078,740 for the three months ended March 31, 2017. This increase was primarily the result of approximately \$85,000 from the impact of manufacturer price increases, approximately \$54,000 from drugs that were new in the past twelve months and approximately \$31,000 from our recent acquisitions. These increases were partially offset by a decrease in hepatitis C business versus the prior year period, reimbursement compression and drug mix.

Cost of Sales — Specialty

Cost of sales for the three months ended March 31, 2018 was \$1,059,924, a \$66,233 or 7 percent increase, compared to \$993,691 for the three months ended March 31, 2017. This increase was primarily the result of the same factors that drove the increase in Specialty's net sales over the same time period. Cost of sales was 91.9 percent and 92.1 percent of net sales for the three months ended March 31, 2018 and 2017, respectively. The slight increase in gross margin from 7.9 percent to 8.1 percent for the three months ended March 31, 2017 and 2018, respectively, was primarily due to the impact of our acquisitions and the impact of manufacturer price increases.

Net Sales & Cost of Sales — PBM

Net sales and cost of sales for the three months ended March 31, 2018 were \$191,468 and \$(173,910), respectively, resulting in a gross profit of \$17,558 and a gross margin of 9.2 percent.

Liquidity and Capital Resources

Our primary uses of cash include funding our ongoing working capital needs, business acquisitions, acquiring and maintaining internal use software and property and equipment, and debt service. Our primary source of liquidity for our working capital is cash flows generated from operations. At various times during the course of the year, we may be in an operating cash usage position, which may require us to use our short-term borrowings. We continuously monitor our working capital position and associated cash requirements and explore opportunities to more effectively manage our inventory and capital spending. As of March 31, 2018 and December 31, 2017, we had \$5,987 and \$84,251, respectively, of cash and cash equivalents. Our cash balances fluctuate based on working capital needs and the timing of sweeping available cash each day to pay down any outstanding balance on our line of credit, which was \$140,000 and \$188,250 at March 31, 2018 and December 31, 2017, respectively. Our available liquidity under our line of credit was \$110,000 and \$61,750 at March 31, 2018 and December 31, 2017, respectively.

We believe that funds generated from operations, cash and cash equivalents on hand, and available borrowing capacity under our line of credit will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. We may enhance our competitive position through additional complementary acquisitions in both existing and new markets. Therefore, from time to time, we may access the equity or debt markets to raise additional funds to finance acquisitions or otherwise on a strategic basis.

The following table provides cash flow data for each of the periods presented:

	Three Months Ended	
	March 31,	
	2017	2016
Net cash provided by operating activities	\$ 48,572	\$ 44,295
Net cash used in investing activities	(2,866)	(28,429)
Net cash used in financing activities	(123,917)	(7,238)
Net (decrease) increase in cash and cash equivalents	\$ (78,211)	\$ 8,628

Cash Flows From Operating Activities

Cash flows from operating activities consists of net income, adjusted for non-cash items and changes in various working capital items, including accounts receivable, inventories, accounts payable and other assets/liabilities.

The \$4,277 increase in cash provided by operating activities for the three months ended March 31, 2018 compared to the three months ended March 31, 2017 was due to a \$8,350 increase in non-cash adjustments to net (loss) income and a \$602 change in net working capital flows, partially offset by a \$4,675 decrease in net income.

Cash Flows From Investing Activities

Our primary investing activities have consisted of business acquisitions, labor expenditures associated with capitalized software for internal use, investments in non-consolidated entities, capital expenditures to purchase computer equipment, software, furniture and fixtures, as well as building improvements to support the expansion of our infrastructure and workforce. As our business grows, our capital expenditures and our investment activity may continue to increase.

The \$25,563 decrease in cash used in investing activities during the three months ended March 31, 2018 compared to the three months ended March 31, 2017 was primarily related to a \$26,532 decrease in cash used to acquire businesses, partially offset by a \$1,016 increase in spending on capitalized software and property and equipment.

Cash Flows From Financing Activities

Our primary financing activities have consisted of debt borrowings and repayments, payment of debt issuance costs, proceeds from stock option exercises, and, historically, proceeds from capital stock offerings and payments made to repurchase capital stock and stock options.

[Table of Contents](#)

The \$116,679 increase in cash used in financing activities during the three months ended March 31, 2018 compared to the three months ended March 31, 2017 was primarily related to a \$75,375 increase in payments on long-term debt, a \$14,713 increase in net payments on the line of credit and the nonrecurrence of a full draw down of our \$25,000 deferred draw term loan during the first quarter of 2017.

Debt

We had \$473,125 and \$550,000 in outstanding term loans as of March 31, 2018 and December 31, 2017, respectively. We also had \$140,000 and \$188,250 outstanding on our line of credit as of March 31, 2018 and December 31, 2017, respectively. We had \$110,000 and \$61,750 available to borrow on our line of credit at March 31, 2018 and December 31, 2017, respectively.

The interest rates we pay under our credit facility are a function of a defined margin above LIBOR. Our Term Loan A and Term Loan B interest rates were 4.38 percent and 6.10 percent, respectively, at March 31, 2018 and 4.04 percent and 6.04 percent, respectively, at December 31, 2017. Our line of credit interest rate was 4.38 percent and 4.04 percent at March 31, 2018 and December 31, 2017, respectively. We are charged a monthly unused commitment fee ranging from 0.3 percent to 0.4 percent on the average unused daily balance on our \$250,000 line of credit.

Our credit facility contains certain financial and non-financial covenants. We were in compliance with all such covenants as of March 31, 2018 and December 31, 2017.

Off-Balance Sheet Arrangements

During the periods presented, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Critical Accounting Policies and Estimates

The MD&A is based on the condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses. In accordance with U.S. GAAP, we base our estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances. Actual results might differ from these estimates under different assumptions or conditions and, to the extent that there are differences between our estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. During the three months ended March 31, 2018, there were no material changes to our critical accounting policies and use of estimates, which are disclosed in our audited consolidated financial statements for the year ended December 31, 2017 included in our Annual Report on Form 10-K, with the exception of our adoption of ASC Topic 606. See Note 3 for further details.

New Accounting Pronouncements

See Note 3 for a description of new accounting pronouncements.

ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

Our operations are solely in the United States of America (“U.S.”) and U.S. Territories and are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate and certain exposure, as well as risks relating to changes in the general economic conditions in the U.S. We are exposed to interest rate fluctuations

with regard to future issuances of fixed-rate debt, and existing and future issuances of floating-rate debt. Primary exposures include the U.S. Prime Rate and LIBOR related to debt outstanding under our credit facility. A 100 basis point increase in 2018 interest rates would have increased our pre-tax loss for the three months ended March 31, 2018 by approximately \$1.8 million.

ITEM 4. CONTROLS AND PROCEDURES

Limitations on Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in our reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the specified time periods in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure .

Our management, with the participation of the chief executive officer and the chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) promulgated under the Exchange Act) as of March 31, 2018. Based on these evaluations, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures required by paragraph (b) of Rule 13a-15 or 15d-15 were effective as of March 31, 2018.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the first quarter of 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On November 10, 2016, a putative class action complaint was filed in the U.S. District Court for the Eastern District of Michigan against Diplomat Pharmacy, Inc. and certain officers of the Company. Following appointment of lead plaintiffs and lead counsel, an amended complaint was filed on April 11, 2017. The amended complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in connection with public filings made between February 29, 2016 and November 2, 2016 (the “potential class period”). The plaintiff seeks to represent a class of shareholders who purchased stock in the potential class period. The complaint seeks unspecified monetary damages and other relief. The Company filed a motion to dismiss the amended complaint on May 24, 2017. The court issued an order denying the Company’s motion to dismiss on January 19, 2018. The Company filed a motion for reconsideration of its motion to dismiss on February 2, 2018. The Company believes the complaint and allegations to be without merit and intends to vigorously defend itself against the action. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on its results of operations, financial condition or cash flows.

On February 10, 2017, the Company’s Board of Directors (the “Board”) received a demand letter from a purported shareholder containing allegations similar to those contained in the putative class action complaint described above. The letter demanded that the Board take action to remedy the alleged violations. In response, the Board established a Special Independent Committee of its disinterested and independent members to investigate the claims. Subsequently, on June 2, 2017, the shareholder filed a putative shareholder’s derivative lawsuit in the Michigan Circuit Court for the County of Genesee regarding the same matters alleged in the demand letter. The complaint names the Company as a nominal defendant and names a number of the Company’s current and former officers and directors as defendants. The complaint seeks unspecified monetary damages and other relief. In connection with the ongoing Special Independent Committee investigation, on July 20, 2017, by agreement between the Company and the shareholder, the court ordered a stay of legal proceedings for 90 days, after which time by further agreement of the Company and the shareholder, the court has extended the stay until July 2, 2018. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on its results of operations, financial condition or cash flows.

The results of legal proceedings are often uncertain and difficult to predict, and the Company could from time to time incur judgments, enter into settlements, materially change its business practices or technologies or revise its expectations regarding the outcome of certain matters. In addition, the costs incurred in litigation can be substantial, regardless of the outcome.

The Company’s business of providing specialized pharmacy services and other related services may subject it to litigation and liability for damages in the ordinary course of business. Nevertheless, the Company believes there are no other legal proceedings, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business, financial position, cash flows, or results of operations.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission on March 1, 2018.

ITEM 5. OTHER INFORMATION

Upon entering into a new Distribution Agreement on May 8, 2018 with Amerisource Bergen Drug Corporation, the parties thereto have terminated the Prime Vendor Agreement, dated January 1, 2012 by and among Amerisource

Bergen Drug Corporation, Diplomat Pharmacy, Inc. and its subsidiaries named therein, as amended, effective as of May 8, 2018.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference			
			Form	Period Ending	Exhibit / Appendix Number	Filing Date
3.1	Bylaws		8-K		3.1	January 5, 2018
10.1*	Form of Restricted Stock Unit Award Agreement (Performance-Based)		8-K		10.1	March 29, 2018
10.2*	Form of Stock Option Award Agreement (Time-Based)		8-K		10.2	March 29, 2018
31.1	Section 302 Certification — CEO	X				
31.2	Section 302 Certification — CFO	X				
32.1**	Section 906 Certification — CEO	X				
32.2**	Section 906 Certification — CFO	X				
101.INS	XBRL Instance Document	X				
101.SCH	XBRL Taxonomy Extension Schema Document	X				
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X				
101.DEF	XBRL Taxonomy Extension Definition Linkbase	X				
101.LAB	XBRL Taxonomy Extension Label Linkbase	X				
101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X				

* Indicates a management contract or compensatory plan or arrangement.

** This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Diplomat Pharmacy, Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jeffrey Park, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2018

By: _____ /s/ JEFFREY PARK
Jeffrey Park
Interim Chief Executive Officer
(Principal Executive Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Diplomat Pharmacy, Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Atul Kavthekar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2018

By: _____ /s/ ATUL KAVTHEKAR
Atul Kavthekar
Chief Financial Officer
(Principal Financial Officer)
